Archive: October 2017

What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? 

Anthony F. Shields, MD, PhD

  H&O  Which patients with colon cancer require adjuvant therapy? AS  Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]

Direct-to-Consumer Advertising of Cancer Treatments

Lowell E. Schnipper, MD

  H&O  What have studies shown about direct-to-consumer advertising of medical treatments? LS  A few studies have evaluated direct-to-consumer advertising of medical treatments, but they are […]

How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver

Mark A. Socinski, MD

Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]

Current Challenges in the Management of Essential Thrombocythemia

Ariel Kleman, MD, Arun K. Singavi, MD, and Laura C. Michaelis, MD

  Abstract: Essential thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms, a category that also includes polycythemia vera and primary myelofibrosis. […]

Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer

Michael T. Schweizer, MD, and Emmanuel S. Antonarakis, MD

  Abstract: Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations […]

When to Initiate Treatment in Smoldering Multiple Myeloma

María-Victoria Mateos, MD, PhD

  H&O  How is smoldering multiple myeloma defined? MM  Smoldering multiple myeloma is a plasma cell dis­order defined by the presence of a serum monoclonal component […]

In the Pipeline: Encorafenib and Binimetinib in BRAF-Mutated Melanoma

Keith Flaherty, MD

  H&O  What makes the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib a good combination for use in BRAF-mutated melanoma? KF  Like other combinations of […]

The Role of Genomics in Patients With Advanced Prostate Cancer

Maha H. Hussain, MD

  H&O  What are the main technologic advances that have spurred on the current interest in genomics? MH  The current interest in genomics was a downstream […]

Hem/Onc News

Devon Schuyler

First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric antigen […]

Letter from the Editor: How to Treat Hodgkin Lymphoma

Brad S. Kahl, MD

  Last weekend, I attended the 2017 ASH Meeting on Hematologic Malignancies. This is an incredible 2-day meeting organized around a series of “How I Treat” […]

Back to Archive